Abstract
In attempt to find new pharmacologically active molecules, we report here the synthesis and in vitro antimicrobial activity of various 3-(1,3,4-oxadiazol-2-yl)-quinazolin-4(3H)-ones. The antimicrobial activity of title compounds were examined against two gram positive bacteria (S. aureus, S. pyogenes), two gram negative bacteria (E. coli, P. aeruginosa) and three fungi (C. albicans, A. niger, A. clavatus) using the broth microdilution method. Some derivatives bearing a bromo or iodo group exhibited very good antimicrobial activity.

Keywords
Antimicrobial activity • 1,3,4-Oxadiazole • Quinazolin-4(3H)-one

Introduction
The chemistry of heterocyclic compounds has been an interesting field of study for a long time. The synthesis of novel oxadiazole derivatives and investigation of their chemical and biological behavior have gained more importance in recent decades for biological, medicinal and agricultural reasons. 1,3,4-Oxadiazoles represent an important class of heterocyclic compounds. Their derivatives possess a broad spectrum of biological activity in both agrochemicals and pharmaceuticals such as insecticidal, herbicidal, antibacterial, antifungal, analgesic, anti-inflammatory, antimalarial, antiviral, anti-HBV, antianxiety, anticancer, anti-HIV, antitubercular and anticonvulsant [1–14]. Quinazolinone nucleus has been gaining prominence due to the fact that its derivatives have been found to possess wide spectrum of pharmacological properties. Quinazolin-4(3H)-one derivatives are useful heterocycles, possessing potent pharmacological activities such as antibacterial, antifungal, analgesic, anti-inflammatory, anthelmintic, anticancer, anticonvulsant,
antihistaminic, anti-HIV, antiproliferative, antitubercular, antiviral, CNS depressant, cytotoxicity, diuretic and hypolipidemic [15–30].

1,3,4-Qxadiazoles and quinazolin-4(3H)-ones having various heterocycles possess wide range of pharmacological properties. The aim of the present work was to attach 1,3,4-oxadiazole residues to quinazolin-4(3H)-one in order to find new biologically active molecules. Thus, the synthesis of novel 1,3,4-oxadiazolyl-quinazolin-4(3H)-one derivatives has been achieved.

Results and Discussion

Chemistry

The title compounds 9a–f, 10a–f and 12a–f were synthesized according to Scheme 2. The structure of all the synthesized compounds were evaluated by spectral data. Benzoic acid derivatives 1a,b were converted in to esters 2a,b using methanol and catalytic amount of sulphuric acid. Esters 2a,b on treatment with hydrazine hydrate yielded corresponding hydrazides 3a,b. The IR spectra of 3a,b showed the absence of ester stretching frequency, instead in gave a band at around 1650 cm⁻¹ for carbonyl group and showing sharp bands in the region of 3300-3435 cm⁻¹ due to -NHNH₂ group. Hydrazides on cyclization reaction with methanolic cyanogen bromide and 4-aminobenzoic acid in phosphorus oxychloride yielded amino substituted 1,3,4-oxadiazoles 4a,b and 5a,b respectively (Scheme 1). 1,3,4-oxadiazole showed C=N stretching at around 1655 cm⁻¹ and C-O-C stretching at around 1270 cm⁻¹ and 1040 cm⁻¹. Signals at around 158 δ ppm and 164 δ ppm confirmed the C-2 and C-5 carbon of 1,3,4-oxadiazole unite.

\[ R^1 = 2-\text{Cl}, 4-\text{Cl} \]

Sch. 1.
Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones

R<sup>1</sup> = 2-Cl, 4-C
R<sup>2</sup> = H, Br, I

Sch. 2.
Substituted benzoxazinones 8a–c were prepared by reaction of acid chloride 6 with substituted anthranilic acid 7a–c in pyridine. Then condensation reaction of 8a–c with 1,3,4-oxadiazoles 4a,b and 5a,b yielded the desired compounds 9a–f and 10a–f. Substituted benzoxazinones 8a–c on reaction with glycine yielded quinazolin-4(3H)-ones 11a–c which on cyclization reaction with hydrazides 3a,b gave the desired compounds 12a–f (Scheme 2). IR spectra showed C=O and C=N stretching frequencies of quinazolinone at around 1680 cm⁻¹ and 1610 cm⁻¹ respectively, further confirmed by ¹³C NMR spectra, which showed C=O and C=N signal at around 160.5 δ ppm and 163.5 δ ppm respectively.

**Antibacterial activity**

**Tab. 1.** Antibacterial activity (MBC, μg/ml) of compounds 4a,b, 5a,b, 9a–f, 10a–f and 12a–f.

| Comp. | R¹ | R² | Gram positive bacteria | Gram negative bacteria |
|-------|----|----|------------------------|------------------------|
|       |    |    | S. aureus MTCC 96 | S. pyogenes MTCC 442 | E. coli MTCC 443 | P. aeruginosa MTCC 1688 |
| 4a    | 2-Cl | –  | 250 | 250 | 50 | 250 |
| 4b    | 4-Cl | –  | 200 | 250 | 250 | 500 |
| 5a    | 2-Cl | –  | 100 | 150 | 250 | 200 |
| 5b    | 4-Cl | –  | 200 | 250 | 500 | 500 |
| 9a    | 2-Cl | H  | 250 | 200 | 500 | 500 |
| 9b    | 2-Cl | Br | 100 | 250 | 200 | 250 |
| 9c    | 2-Cl | I  | 500 | 500 | 100 | 250 |
| 9d    | 4-Cl | H  | 200 | 250 | 200 | 250 |
| 9e    | 4-Cl | Br | 250 | 250 | 250 | 150 |
| 9f    | 4-Cl | I  | 500 | 1000 | 250 | 200 |
| 10a   | 2-Cl | H  | 150 | 250 | 500 | 500 |
| 10b   | 2-Cl | Br | 500 | 1000 | 250 | 500 |
| 10c   | 2-Cl | I  | 100 | 150 | 150 | 500 |
| 10d   | 4-Cl | H  | 500 | 500 | 200 | 250 |
| 10e   | 4-Cl | Br | 250 | 250 | 150 | 250 |
| 10f   | 4-Cl | I  | 62.5 | 150 | 100 | 250 |
| 12a   | 2-Cl | H  | 500 | 500 | 250 | 250 |
| 12b   | 2-Cl | Br | 500 | 500 | 100 | 50 |
| 12c   | 2-Cl | I  | 50 | 250 | 125 | 200 |
| 12d   | 4-Cl | H  | 500 | 500 | 150 | 200 |
| 12e   | 4-Cl | Br | 500 | 250 | 100 | 250 |
| 12f   | 4-Cl | I  | 200 | 200 | 50 | 150 |
| Ampicillin | –  | –  | 250 | 100 | 100 | 100 |

The minimal bactericidal concentrations of the tested compounds are shown in Tab. 1. The three different series of 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones 9a–f, 10a–f and 12a–f were tested for **in vitro** antibacterial activity against two gram positive bacteria (S. aureus MTCC 96, S. pyogenes MTCC 442) and two gram negative bacteria (E. coli MTCC 443, P. aeruginosa MTCC 1688). Ampicillin was used as a standard drug. Results showed that,
most of the compounds possessed very good antibacterial activity (MBC = 50-250 μg/ml) against gram positive bacteria *S. aureus*. Some of the compounds possessed excellent activity as compared to ampicillin. Compounds 5a, 9b, 10a, 10c, 10f and 12c showed MBC value in the range between 50–150 μg/ml while standard drug ampicillin itself had MBC value of 250 μg/ml against gram positive bacteria *S. aureus*. Compounds 4a, 4b, 5b, 9a, 9d, 9e, 10e and 12f imparted parallel activity as ampicillin with MBC in the range 200-250 μg/ml. 5a, 10c and 10f have MBC at 150 μg/ml which were comparatively good as ampicillin against *S. pyogenes*. 4a and 12f showed excellent activity at 50 μg/ml while 9c, 10f, 12b and 12e possessed good activity at 100 μg/ml against gram negative bacteria *E. coli* as compared to ampicillin. Compound 12b showed excellent activity at 50 μg/ml, while 9e and 12f exhibited good activity at 150 μg/ml against *P. aeruginosa*. The remaining compounds of the three different series possessed moderate to poor activities.

**Antifungal activity**

**Tab. 2.** Antifungal activity (MFC, μg/ml) of compds. 4a,b, 5a,b, 9a–f, 10a–f and 12a–f.

| Comp. | R¹   | R² | C. albicans MTCC 227 | A. niger MTCC 282 | A. clavatus MTCC 1323 |
|-------|------|----|---------------------|-------------------|-----------------------|
| 4a    | 2-Cl | –  | 250                 | 1000              | 1000                  |
| 4b    | 4-Cl | –  | >1000               | >1000             | >1000                 |
| 5a    | 2-Cl | –  | 500                 | 500               | 500                   |
| 5b    | 4-Cl | –  | 500                 | >1000             | >1000                 |
| 9a    | 2-Cl H|     | 500                 | 250               | 250                   |
| 9b    | 2-Cl Br|    | 500                 | 500               | 500                   |
| 9c    | 2-Cl I|    | 500                 | >1000             | >1000                 |
| 9d    | 4-Cl H|     | 500                 | 250               | 250                   |
| 9e    | 4-Cl Br|    | 500                 | 500               | 500                   |
| 9f    | 4-Cl I|    | 250                 | 200               | 200                   |
| 10a   | 2-Cl H|     | >1000               | >1000             | >1000                 |
| 10b   | 2-Cl Br|   | 250                 | 500               | >1000                 |
| 10c   | 2-Cl I|    | >1000               | >1000             | >1000                 |
| 10d   | 4-Cl H|     | 500                 | >1000             | >1000                 |
| 10e   | 4-Cl Br|    | 500                 | >1000             | >1000                 |
| 10f   | 4-Cl I|    | 250                 | 500               | 500                   |
| 12a   | 2-Cl H|     | >1000               | 500               | >1000                 |
| 12b   | 2-Cl Br|   | 250                 | 500               | 250                   |
| 12c   | 2-Cl I|    | 100                 | 200               | 200                   |
| 12d   | 4-Cl H|     | >1000               | >1000             | >1000                 |
| 12e   | 4-Cl Br|   | 500                 | >1000             | 500                   |
| 12f   | 4-Cl I|    | 200                 | >1000             | 500                   |
| Griseofulvin | – | – | 500                 | 100               | 100                   |

Minimal fungicidal concentrations of the synthesized compounds are shown in Table 2. For *in vitro* antifungal activity, three fungal species *C. albicans* MTCC 227, *A. niger* MTCC 282 and *A. clavatus* MTCC 1323 were used and compared with standard drug griseofulvin. Most of the compounds possessed very good antifungal activity against *C. albicans*. Their
MFC values are in the range between 100-500 μg/ml. Compound 12c showed excellent activity at 100 μg/ml whereas compounds 4a, 9f, 10b, 10f, 12b and 12f possessed very good activity at 200-250 μg/ml while 5a,b, 9a–e, 10d,e and 12e share similar activities as griseofulvin which was 500 μg/ml against C. albicans. Compounds 9a, 9d, 9f and 12c showed moderate activities with MFC of 200-250 μg/ml against A. niger and A. clavatus. The remaining compounds displayed poor activities against both fungal species A. niger and A. clavatus as compared to control drug griseofulvin.

**Experimental**

**Chemistry**

All chemical were of analytical grade and used directly. Melting points were determined in PMP-DM scientific melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer RX 1 FTIR spectrophotometer, using potassium bromide pellets and the frequencies are expressed in cm$^{-1}$. The $^1$H NMR and $^{13}$C NMR spectra were recorded with a Bruker Avance II 400 NMR spectrometer, using tetramethylsilane as the internal reference, with dimethylsulphoxide DMSO-d$_6$ as solvent. The chemical shifts are reported in parts per million (ppm). Elemental analyses were performed on a Heraeus Carlo Erba 1180 CHN analyzer. The purity of compounds was confirmed by TLC using Merck silica gel 60 F254 plates using toluene:ethylacetate:methanol (7:2:1) as a mobile phase and spots were visualized under UV radiation. 2-[(2,6-Dichlorophenyl)amino]phenyl]acetyl chloride (6) was synthesized by the literature procedure [31].

**General procedure for esters (2a,b)**

Substituted benzoic acid 1a,b (20 mmol) and 30 ml methanol was refluxed on water bath for 5–8 h in a few drops of concentrated sulfuric acid as a catalyst. After completion of the reaction, it was poured onto ice cold water. The obtained solid was washed with sodium bicarbonate solution (5%), dried and recrystallized twice from methanol.

*Methyl 2-chlorobenzoate (2a)*

Yield: 75%, bp: 232–236°C. IR (KBr), v, cm$^{-1}$: 740 (C-Cl), 2856, 2960 (CH$_3$), 1286, 1121 (C-O-C), 1722 (C=O).

*Methyl 4-chlorobenzoate (2b)*

Yield: 72%, mp: 40–45°C. IR (KBr), v, cm$^{-1}$: 742 (C-Cl), 2852, 2959 (CH$_3$), 1282, 1119 (C-O-C), 1720 (C=O).

**General procedure for hydrazides (3a,b)**

To a solution of methyl benzoates 2a,b (10 mmol) in 15 ml methanol was added hydrazine hydrate (20 mmol). The reaction mixture was refluxed on a water bath for 8–10 h and allowed to stand overnight. The crystals formed were filtered, washed and after drying recrystallized from methanol.

*2-Chlorobenzohydrazide (3a)*

Yield: 70%, mp: 112–116°C. IR (KBr), v, cm$^{-1}$: 742 (C-Cl), 1650 (C=O), 3308 (NH), 3429, 3348 (NH$_2$).
4-Chlorobenzohydrazide (3b)
Yield: 67%, mp: 163–166°C. IR (KBr), ν, cm⁻¹: 745 (C-Cl), 1645 (C=O), 3310 (NH), 3433, 3352 (NH₂).

General procedure for 5-substituted phenyl-1,3,4-oxadiazol-2-amines (4a,b)
To the 10 ml methanolic solution of substituted benzohydrazides 3a,b (5 mmol), cyanogen bromide (7.5 mmol) was added. The reaction mixture was refluxed on water bath for 5–7 h. The resulting solution was cooled and neutralized with sodium bicarbonate solution (5% w/v). The solid thus separated out was filtered, washed with water, dried and recrystallized from methanol.

5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-amine (4a)
Yield: 62%, mp: 165–168°C, lit. 164–166°C [32]. IR (KBr), ν, cm⁻¹: 742 (C-Cl), 1265, 1036 (C-O-C), 1649 (C=N), 3470, 3402 (NH₂). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 7.35 (bs, 2H, NH₂), 7.49 (t, J = 7.52 Hz, 1H, H-9), 7.55 (t, J = 7.36 Hz, 1H, H-10), 7.65 (d, J = 7.8 Hz, 1H, H-8), 7.70 (d, J = 7.48 Hz, 1H, H-11). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 127.53 (C-10), 128.12 (C-11), 128.69 (C-8), 129.81 (C-9), 131.43 (C-7), 135.18 (C-6), 157.53 (C-2), 163.50 (C-5). Anal. Calcd. for C₈H₆N₃OCl: C, 49.12; H, 3.09; N, 21.48. Found: C, 49.25; H, 3.14; N, 21.41.

5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-amine (4b)
Yield: 70%, mp: 243–245°C, lit. 231–233°C [32]. IR (KBr), ν, cm⁻¹: 745 (C-Cl), 1277, 1043 (C-O-C), 1662 (C=N), 3480, 3396 (NH₂). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 7.37 (bs, 2H, NH₂), 7.62 (d, J = 8.24 Hz, 2H, H-8,10), 7.69 (d, J = 8.24 Hz, 2H, H-7,11). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 123.34 (C-6), 131.78 (C-7,11), 133.20 (8,10), 135.42 (C-9), 157.58 (C-2), 163.56 (C-5). Anal. Calcd. for C₈H₆N₃OCl: C, 49.12; H, 3.09; N, 21.48. Found: C, 48.98; H, 3.17; N, 21.56.

General procedure for 4-(5-substitutedphenyl-1,3,4-oxadiazol-2-yl)benzenamines (5a,b)
A mixture of 4-aminobenzoic acid (5 mmol) and substituted benzohydrazides 3a,b (5 mmol) in 5 ml phosphorus oxychloride was refluxed on water bath for 7–10 h. After the completion of reaction, it was cooled and poured onto crushed ice with continuous stirring. The solid mass separated was neutralized with sodium bicarbonate solution (10% w/v). The resulting solid thus obtained was collected by filtration, washed well with cold water, dried and recrystallized from absolute ethanol.
Fig. 2. Numbering of 4-(5-substituted phenyl-1,3,4-oxadiazol-2-yl)benzenamines 5a,b

4-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenamine (5a)
Yield: 63%, mp: 175–178°C. IR (KBr), ν, cm⁻¹: 746 (C-Cl), 1266, 1042 (C-O-C), 1653 (C=N), 3482, 3380 (NH₂). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 5.46 (bs, 2H, NH₂), 6.80 (d, J = 8.32 Hz, 2H, H-8,10), 7.31 (d, J = 8.32 Hz, 2H, H-7,11), 7.50 (t, J = 7.56 Hz, 1H, H-15), 7.56 (t, J = 7.4 Hz, 1H, H-16), 7.64 (d, J = 7.84 Hz, 1H, H-14), 7.68 (d, J = 7.5 Hz, 1H, H-17). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 108.13 (C-6), 114.84 (C-8,10), 127.53 (C-16), 128.14 (C-17), 128.62 (C-7,11), 128.74 (C-14), 129.85 (C-15), 131.38 (C-13), 135.22 (C-12), 148.48 (C-9), 162.37 (C-2,5). Anal. Calcd. for C₁₄H₁₀N₃OCl: C, 61.89; H, 3.71; N, 15.47. Found: C, 61.76; H, 3.75; N, 15.39.

4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]benzenamine (5b)
Yield: 65%, mp: 210–214°C, lit. 210–212°C [12]. IR (KBr), ν, cm⁻¹: 743 (C-Cl), 1268, 1040 (C-O-C), 1658 (C=N), 3482, 3375 (NH₂). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 5.45 (bs, 2H, NH₂), 6.79 (d, J = 8.36 Hz, 2H, H-8,10), 7.29 (d, J = 8.36 Hz, 2H, H-7,11), 7.63 (d, J = 8.2 Hz, 2H, H-14,16), 7.68 (d, J = 8.2 Hz, 2H, H-13,17). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 107.42 (C-6), 114.45 (C-8,10), 123.31 (C-12), 128.73 (C-7,11), 131.82 (C-13,17), 133.24 (C-14,16), 135.44 (C-15), 148.53 (C-9), 161.89 (C-2,5). Anal. Calcd. for C₁₄H₁₀N₃OCl: C, 61.89; H, 3.71; N, 15.47. Found: C, 61.78; H, 3.66; N, 15.54.

General procedure for benzoxazinones (8a–c)
A mixture of {2-{[2,6-Dichlorophenyl]amino}phenyl}acetyl chloride (6) (10 mmol) and substituted anthranilic acids 7a–c (10 mmol) in 20 ml pyridine were stirred at 0–5°C for 1 h, further stirred for 1 h at room temperature. After completion of reaction, a pasty mass obtained, was washed thoroughly with sodium bicarbonate (5 % w/v) to remove unreacted acid. A solid separated was filtered, dried and recrystallized from methanol.

Fig. 3. Numbering of Benzoxazinones 8a–c
2-[2-(2,6-Dichlorophenyl)amino]benzyl-4H-3,1-benoxazin-4-one (8aF)

Yield: 53%, mp: 183–186°C, lit. 185–187°C [33]. IR (KBr), ν, cm⁻¹: 745 (C=Cl), 1151 (C=O), 1316 (C=N), 1620 (C=O), 2925, 2851 (CH₂), 3449 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.52 (s, 2H, H-11), 6.39 (d, J = 7.96 Hz, 1H, H-14), 6.88 (t, J = 7.4 Hz, 1H, H-16), 7.04–7.09 (m, 2H, H-15, 22), 7.21 (d, J = 7.54 Hz, 1H, H-17), 7.42 (d, J = 8.08 Hz, 2H, H-21,23), 7.51 (d, J = 8.12 Hz, 1H, H-8), 7.84 (t, J = 7.8 Hz, 1H, H-7), 8.06 (t, J = 7.64 Hz, 1H, H-6), 8.12 (d, J = 7.72 Hz, 1H, H-5), 9.12 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 32.47 (C-11), 116.54 (C-10), 120.54 (C-14), 122.35 (C-8), 124.15 (C-22), 126.61 (C-15), 127.12 (C-12), 127.32 (C-12), 127.32 (C-21,23), 127.54 (C-6), 129.34 (C-20,24), 131.23 (C-17), 131.52 (C-5), 135.43 (C-7), 137.23 (C-19), 141.76 (C-13), 149.53 (C-9), 159.36 (C-4), 164.51 (C-2). Anal. Calcd. for C₂₁H₁₄Cl₂N₂O₂: C, 63.49; H, 3.55; N, 7.05. Found: C, 63.45; H, 3.56; N, 7.03.

6-Bromo-2-[2-(2,6-dichlorophenyl)amino]benzyl-4H-3,1-benoxazin-4-one (8b)

Yield: 55%, mp: 194–198°C, lit. 193–196°C [34]. IR (KBr), ν, cm⁻¹: 565 (C-Br), 743 (C=O), 1153 (C-O), 1318 (C=N), 1618 (C=O), 2926, 2850 (CH₂), 3446 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.53 (s, 2H, H-11), 6.40 (d, J = 8 Hz, 1H, H-14), 6.88 (t, J = 7.44 Hz, 1H, H-16), 7.03–7.08 (m, 2H, H-15,22), 7.22 (d, J = 7.58 Hz, 1H, H-17), 7.41 (d, J = 8.16 Hz, 2H, H-21,23), 7.65 (d, J = 8.32 Hz, 1H, H-8), 8.12 (d, J = 8.32 Hz, 1H, H-7), 8.16 (s, 1H, H-5), 9.10 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 32.43 (C-11), 116.31 (C-16), 118.64 (C-10), 120.62 (C-14), 121.67 (C-12), 124.31 (C-22), 124.57 (C-8), 126.54 (C-15), 127.17 (C-12), 127.43 (C-21,23), 129.41 (C-20,24), 131.12 (C-17), 135.22 (C-5), 137.29 (C-19), 138.23 (C-7), 141.78 (C-13), 148.73 (C-9), 159.23 (C-4), 164.33 (C-2). Anal. Calcd. for C₂₁H₁₃BrCl₂N₂O₂: C, 52.97; H, 2.75; N, 5.88. Found: C, 52.94; H, 2.74; N, 5.90.

2-[2-(2,6-Dichlorophenyl)amino]benzyl-6-iodo-4H-3,1-benoxazin-4-one (8c)

Yield: 58%, mp: 189–193°C, lit. 193–196°C [35]. IR (KBr), ν, cm⁻¹: 620 (C-Br), 745 (C=O), 1186.64 (C=O), 120.62 (C-14), 124.67 (C-6), 124.31 (C-22), 124.57 (C-8), 126.54 (C-15), 127.17 (C-12), 127.43 (C-21,23), 129.41 (C-20,24), 131.12 (C-17), 135.22 (C-5), 137.29 (C-19), 138.23 (C-7), 141.78 (C-13), 148.73 (C-9), 159.23 (C-4), 164.33 (C-2). Anal. Calcd. for C₂₁H₁₃Cl₂I₂N₂O₂: C, 48.27; H, 2.75; N, 5.88. Found: C, 48.21; H, 2.50; N, 5.35. Found: C, 48.25; H, 2.49; N, 5.33.

General procedure for 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones (9a–f)

A mixture of benoxazinones 8a–c (2.5 mmol) and 5-substituted phenyl-1,3,4-oxadiazol-2-amines 4a,b (2.5 mmol) in 10 ml glacial acetic acid was refluxed under anhydrous condition for 4–6 h. After cooling it was poured into crushed ice. The solid separated out was filtered, thoroughly washed with cold distilled water, dried, and recrystallized from ethanol.
Fig. 4. Numbering of 1,3,4-Oxadiazolyl-quinazolin-4(3H)-ones 9a–f

3-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}–quinazolin-4(3H)-one (9a)

Yield: 63%, mp: 233–235°C. IR (KBr), v, cm⁻¹: 746 (C-Cl), 1318 (C-N), 1263, 1037 (C-O-C oxadiazole), 1609 (C=N quinazolinone), 1650 (C=N oxadiazole), 2926, 2853 (CH₂), 3445 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.52 (s, 2H, H-11), 6.41 (d, J = 7.96 Hz, 1H, H-14), 6.89 (t, J = 7.4 Hz, 1H, H-16), 7.03-7.09 (m, 2H, H-15,22), 7.22 (d, J = 7.54 Hz, 1H, H-17), 7.41 (d, J = 8.08 Hz, 2H, H-21,23), 7.47 (t, J = 7.68 Hz, 1H, H-6), 7.50 (t, J = 7.56 Hz, 1H, H-33), 7.57 (t, J = 7.4 Hz, 1H, H-34), 7.61 (d, J = 8.16 Hz, 1H, H-8), 7.65 (d, J = 7.84 Hz, 1H, H-32), 7.71 (d, J = 7.52 Hz, 1H, H-35), 7.76 (t, J = 7.84 Hz, 1H, H-7), 8.10 (d, J = 7.76 Hz, 1H, H-5), 9.09 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 32.54 (C-11), 116.32 (C-16), 120.41 (C-14), 120.77 (C-10), 122.54 (C-8), 124.31 (C-22), 126.54 (C-15), 127.21 (C-12), 127.39 (C-21,23), 127.49 (C-34), 127.58 (C-6), 128.12 (C-35), 128.55 (C-32), 128.76 (C-5), 129.35 (C-20,24), 129.81 (C-33), 131.17 (C-17), 131.45 (C-31), 133.66 (C-7), 135.24 (C-30), 137.32 (C-19), 141.68 (C-13), 147.15 (C-9), 156.72 (C-26), 160.74 (C-4), 163.27 (C-2), 164.65 (C-29). Anal. Calcd. for C₂₉H₁₈Cl₃N₅O₂: C, 60.59; H, 3.16; N, 12.18. Found: C, 60.54; H, 3.11; N, 12.21.

6-Bromo-3-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}quinazolin-4(3H)-one (9b)

Yield: 55%, mp: 225–228°C. IR (KBr), v, cm⁻¹: 570 (C-Br), 745 (C-Cl), 1311 (C-N), 1260, 1035 (C-O-C oxadiazole), 1611 (C=N quinazolinone), 1653 (C=N oxadiazole), 1675 (C=O quinazolinone), 2925, 2851 (CH₂), 3447 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.53 (s, 2H, H-11), 6.39 (d, J = 8 Hz, 1H, H-14), 6.89 (t, J = 7.44 Hz, 1H, H-16), 7.03-7.09 (m, 2H, H-15,22), 7.21 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.16 Hz, 2H, H-21,23), 7.51 (t, J = 7.52 Hz, 1H, H-33), 7.55 (t, J = 7.36 Hz, 1H, H-34), 7.61 (d, J = 8.24 Hz, 1H, H-8), 7.66 (d, J = 7.8 Hz, 1H, H-32), 7.70 (d, J = 7.48 Hz, 1H, H-35), 8.08 (d, J = 8.24 Hz, 1H, H-7), 8.12 (s, 1H, H-5), 9.08 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 32.65 (C-11), 116.24 (C-16), 120.53 (C-14), 123.13 (C-10), 124.24 (C-22), 124.58 (C-8), 126.47 (C-15), 127.18 (C-12), 127.37 (C-21,23), 127.48 (C-34), 127.66 (C-6), 128.15 (C-33), 128.72 (C-32), 129.34 (C-20,24), 129.79 (C-33), 131.16 (C-17), 131.47 (C-31), 132.25 (C-5), 135.21 (C-30), 136.37 (C-7), 137.36 (C-19), 141.77 (C-13), 146.21 (C-9), 156.64 (C-26), 160.59 (C-4), 163.38 (C-2), 164.57 (C-29). Anal. Calcd. for C₂₉H₁₇BrCl₃N₅O₂: C, 53.28; H, 2.62; N, 10.71. Found: C, 53.19; H, 2.65; N, 10.75.
3-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-[2-(2,6-dichlorophenyl)amino]benzyl]-6-iodoquinazolin-4(3H)-one (9c)

Yield: 66%, mp: 241–244°C. IR (KBr), ν, cm⁻¹: 618 (C-I), 740 (C-Cl), 1317 (C=N), 1262, 1042 (C-O-C oxadiazole), 1608 (C=N quinazolinone), 1684 (C=N oxadiazole), 1684 (C=O quinazolinone), 2928, 2854 (CH₂), 3449 (NH).

1H NMR (400 MHz, DMSO-d₆, TMS): δ 3.52 (s, 2H, H-11), 6.40 (d, J = 7.92 Hz, 1H, H-14), 7.21 (d, J = 7.5 Hz, 1H, H-17), 7.25 (d, J = 8.28 Hz, 1H, H-8), 7.41 (d, J = 8.12 Hz, 2H, H-21,22), 7.48 (t, J = 7.56 Hz, 1H, H-33), 7.55 (t, J = 7.9 Hz, 1H, H-36), 7.64 (d, J = 7.84 Hz, 1H, H-35), 7.93 (d, J = 8.28 Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.11 (bs, 1H, H-18).

13C NMR (100 MHz, DMSO-d₆, TMS): δ 32.95 (C-11), 93.15 (C-6), 116.25 (C-16), 120.44 (C-14), 122.56 (C-10), 124.02 (C-8), 124.23 (C-22), 126.50 (C-15), 127.13 (C-12), 127.34 (C-21,23), 127.57 (C-34), 128.14 (C-35), 128.71 (C-32), 129.47 (C-20), 129.82 (C-33), 131.30 (C-31), 131.46 (C-31), 131.59 (C-30), 136.24 (C-5), 137.35 (C-19), 141.78 (C-13), 142.43 (C-7), 146.11 (C-9), 156.69 (C-26), 160.88 (C-4), 163.35 (C-2), 164.61 (C-29). Anal. Calcd. for C₂₉H₁₇Cl₃IN₅O₂: C, 49.71; H, 2.45; N, 9.99. Found: C, 49.66; H, 2.51; N, 10.02.

3-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-[2-(2,6-dichlorophenyl)amino]benzyl]-quinazolin-4(3H)-one (9d)

Yield: 65%, mp: 260–265°C. IR (KBr), ν, cm⁻¹: 748 (C-Cl), 1315 (C-N), 1264, 1038 (C-O-C oxadiazole), 1612 (C=N quinazolinone), 1648 (C=N oxadiazole), 1675 (C=O quinazolinone), 2923, 2848 (CH₂), 3442 (NH).

1H NMR (400 MHz, DMSO-d₆, TMS): δ 3.51 (s, 2H, H-11), 6.38 (d, J = 8.04 Hz, 1H, H-14), 6.89 (t, J = 7.48 Hz, 1H, H-17), 7.43 (d, J = 8.12 Hz, 2H, H-21,23), 7.49 (t, J = 7.6 Hz, 1H, H-6), 7.61 (d, J = 8.08 Hz, 1H, H-8), 7.65 (d, J = 8.24 Hz, 2H, H-32,34), 7.70 (d, J = 8.24 Hz, 2H, H-31,35), 7.74 (t, J = 7.8 Hz, 1H, H-7), 8.11 (d, J = 7.72 Hz, 1H, H-5), 9.07 (bs, 1H, H-18).

13C NMR (100 MHz, DMSO-d₆, TMS): δ 32.51 (C-11), 116.30 (C-16), 120.43 (C-14), 120.75 (C-10), 122.52 (C-8), 123.32 (C-30), 124.33 (C-22), 126.57 (C-15), 127.13 (C-12), 127.34 (C-21,23), 127.57 (C-34), 128.14 (C-35), 128.78 (C-32), 129.47 (C-20), 129.82 (C-33), 131.30 (C-31), 131.46 (C-31), 131.59 (C-30), 136.24 (C-5), 137.35 (C-19), 141.78 (C-13), 142.43 (C-7), 146.11 (C-9), 156.69 (C-26), 160.88 (C-4), 163.35 (C-2), 164.61 (C-29). Anal. Calcd. for C₂₉H₁₈Cl₃N₅O₂: C, 60.59; H, 3.16; N, 12.18. Found: C, 60.51; H, 3.19; N, 12.15.

6-Bromo-3-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-[2-(2,6-dichlorophenyl)amino]benzyl]-quinazolin-4(3H)-one (9e)

Yield: 61%, mp: 254–258°C. IR (KBr), ν, cm⁻¹: 568 (C-Br), 743 (C-Cl), 1316 (C-N), 1258, 1032 (C-O-C oxadiazole), 1613 (C=N quinazolinone), 1650 (C=N oxadiazole), 1674 (C=O quinazolinone), 2923, 2849 (CH₂), 3444 (NH).

1H NMR (400 MHz, DMSO-d₆, TMS): δ 3.52 (s, 2H, H-11), 6.41 (d, J = 8 Hz, 1H, H-14), 6.90 (t, J = 7.44 Hz, 1H, H-16), 7.04-7.10 (m, 2H, H-15,22), 7.20 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.08 Hz, 2H, H-21,23), 7.60 (d, J = 8.32 Hz, 1H, H-8), 7.64 (d, J = 8.2 Hz, 2H, H-32,34), 7.69 (d, J = 8.2 Hz, 2H, H-31,35), 8.01 (d, J = 8.32 Hz, 1H, H-7), 8.09 (s, 1H, H-5), 9.08 (bs, 1H, H-18).

13C NMR (100 MHz, DMSO-d₆, TMS): δ 32.57 (C-11), 116.28 (C-16), 120.56 (C-14), 123.16 (C-10), 123.33 (C-30), 124.27 (C-22), 124.56 (C-8), 126.48 (C-15), 127.22 (C-12), 127.39 (C-21,23), 127.67 (C-6), 129.35 (C-20,24), 131.18 (C-17), 131.79 (C-31,35), 132.24 (C-5), 133.24 (C-32,34), 135.39 (C-33), 136.35 (C-7), 137.38 (C-19), 141.76 (C-13), 146.23 (C-9), 156.58 (C-26), 164.77 (C-29). Anal. Calcd. for C₂₉H₁₈Cl₃N₅O₂: C, 60.59; H, 3.16; N, 12.18. Found: C, 60.51; H, 3.19; N, 12.15.
160.61 (C-4), 163.41 (C-2), 164.54 (C-29). Anal. Calcd. for C_{29}H_{17}BrCl_{3}N_{5}O_{2}: C, 53.28; H, 2.62; N, 10.71. Found: C, 53.35; H, 2.66; N, 10.58.

3-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}-6-iodoquinazolin-4(3H)-one (9f)

Yield: 68%, mp: 273–277°C. IR (KBr), v, cm$^{-1}$: 615 (C-I), 746 (C-Cl), 1315 (C-N), 1260, 1045 (C-O-C oxadiazole), 1612 (C=N quinazolinone), 1651 (C=N oxadiazole), 1680 (C=O quinazolinone), 2927, 2852 (CH$_2$), 3450 (NH). $^1$H NMR (400 MHz, DMSO-$d_6$, TMS): $\delta$ 3.51 (s, 2H, H-11), 6.41 (d, $J = 7.92$ Hz, 1H, H-14), 6.88 (t, $J = 7.36$ Hz, 1H, H-16), 7.05-7.08 (m, 2H, H-15,22), 7.21 (d, $J = 7.54$ Hz, 1H, H-17), 7.25 (d, $J = 8.36$ Hz, 1H, H-8), 7.41 (d, $J = 8.12$ Hz, 2H, H-21,23), 7.62 (d, $J = 8.28$ Hz, 2H, H-32,34), 7.68 (d, $J = 8.28$ Hz, 2H, H-31,35), 7.95 (d, $J = 8.36$ Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.11 (bs, 1H, H-18). $^{13}$C NMR (100 MHz, DMSO-$d_6$, TMS): $\delta$ 33.05 (C-11), 93.18 (C-6), 116.29 (C-16), 120.42 (C-14), 122.58 (C-10), 123.30 (C-30), 124.08 (C-8), 124.25 (C-22), 126.52 (C-15), 127.16 (C-12), 127.35 (C-21,23), 129.46 (C-20,24), 131.32 (C-17), 131.77 (C-31,35), 133.25 (C-32,34), 135.41 (C-33), 136.23 (C-5), 137.34 (C-19), 141.76 (C-13), 142.45 (C-7), 146.13 (C-9), 156.65 (C-26), 160.89 (C-4), 163.37 (C-2), 164.62 (C-29). Anal. Calcd. for C$_{29}$H$_{17}$Cl$_3$IN$_5$O$_2$: C, 49.71; H, 2.45; N, 9.99. Found: C, 49.65; H, 2.47; N, 10.04.

General procedure for 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones (10a-f)

A mixture of benzoxazinones 8a–c (2.5 mmol) and 4-(5-substituted phenyl-1,3,4-oxadiazol-2-yl)benzenamines 5a,b (2.5 mmol) 10 ml in pyridine was refluxed on an oil bath for 6-8 h. After completion of the reaction, the oily mass was slowly poured onto crushed ice cold water containing 5 ml concentrated HCl with continues stirring. The product obtained was filtered and washed several times with cold water, dried and recrystallized from ethanol.

Fig. 5. Numbering of 1,3,4-Oxadiazolyl-quinazolin-4(3H)-ones 10a–f

3-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl]-2-{2-[(2,6-dichlorophenyl)amino]benzyl}quinazolin-4(3H)-one (10a)

Yield: 62%, mp: 228–231°C. IR (KBr), v, cm$^{-1}$: 740 (C-Cl), 1316 (C-N), 1265, 1041 (C-O-C oxadiazole), 1610 (C=N quinazolinone), 1656 (C=N oxadiazole), 1676 (C=O quinazolinone), 2925, 2852 (CH$_2$), 3446 (NH). $^1$H NMR (400 MHz, DMSO-$d_6$, TMS): $\delta$ 3.51 (s, 2H, H-11), 6.40 (d, $J = 8$ Hz, 1H, H-14), 6.89 (t, $J = 7.4$ Hz, 1H, H-16), 7.03-7.09 (m,
6-Bromo-3-{4-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)-amino]benzyl}-6-iodoquinazolin-4(3H)-one (10b)

Yield: 64%, mp: 213–217°C. IR (KBr), ν, cm⁻¹: 572 (C=Br), 743 (C-Cl), 1312 (C-N), 1268, 1048 (C-O-C quinazolino1), 1609 (C=N oxazolo1), 1653 (C-N oxazolo2), 1681 (C-O quinazolino1), 2921, 2847 (CH₂), 3442 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.53 (s, 2H, H-11), 6.42 (d, J = 7.96 Hz, 1H, H-14), 6.91 (t, J = 7.44 Hz, 1H, H-16), 7.03-7.10 (m, 2H, H-15,22), 7.23 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.12 Hz, 2H, H-21,23), 7.45 (d, J = 8.36 Hz, 2H, H-26,30), 7.48 (t, J = 7.56 Hz, 1H, H-39), 7.54 (t, J = 7.4 Hz, 1H, H-40), 7.57 (d, J = 8.36 Hz, 2H, H-27,29), 7.61 (d, J = 8.4 Hz, 1H, H-8), 7.65 (d, J = 7.8 Hz, 1H, H-38), 7.72 (d, J = 7.48 Hz, 1H, H-41), 8.05 (d, J = 8.4 Hz, 1H, H-7), 8.12 (s, 1H, H-5), 9.11 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 32.63 (C-11), 116.27 (C-16), 120.55 (C-14), 121.52 (C-28), 121.78 (C-26,30), 123.12 (C-10), 124.26 (C-22), 124.62 (C-8), 126.50 (C-15), 127.17 (C-12), 127.38 (C-21,23), 127.53 (C-40), 127.64 (C-6), 127.73 (C-27,29), 128.17 (C-41), 128.76 (C-38), 129.37 (C-20,24), 129.82 (C-39), 131.20 (C-17), 131.45 (C-37), 132.27 (C-5), 132.64 (C-25), 135.23 (C-36), 136.35 (C-7), 137.32 (C-19), 141.74 (C-13), 146.23 (C-9), 160.60 (C-4), 163.28 (C-2), 164.59 (C-32,35). Anal. Calcd. for C₃₅H₂₂BrCl₃N₅O₂: C, 65.48; H, 3.41; N, 10.76. Found: C, 64.51; H, 3.46; N, 10.71.

3-{4-[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)amino]benzyl}-6-iodoquinazolin-4(3H)-one (10c)

Yield: 60%, mp: 235–238°C. IR (KBr), ν, cm⁻¹: 620 (C-I), 748 (C-Cl), 1312 (C-N), 1270, 1051 (C-O-C quinazolino1), 1611 (C=N quinazolino1), 1649 (C=N oxadiazolo1), 1768 (C-O quinazolino1), 2928, 2855 (CH₂), 3448 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.52 (s, 2H, H-11), 6.41 (d, J = 8 Hz, 1H, H-14), 6.88 (t, J = 7.44 Hz, 1H, H-16), 7.05-7.11 (m, 2H, H-15,22), 7.23 (d, J = 7.54 Hz, 1H, H-17), 7.26 (d, J = 8.32 Hz, 1H, H-8), 7.43 (d, J = 8.04 Hz, 2H, H-21,23), 7.46 (d, J = 8.44 Hz, 2H, H-26,30), 7.49 (t, J = 7.6 Hz, 1H, H-39), 7.53 (d, J = 8.44 Hz, 2H, H-27,29), 7.56 (t, J = 7.42 Hz, 1H, H-40), 7.63 (d, J = 7.88 Hz, 1H, H-38), 7.69 (d, J = 7.56 Hz, 1H, H-41), 7.93 (d, J = 8.32 Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.09 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 32.90 (C-11), 93.21 (C-6), 116.29 (C-16), 120.48 (C-14), 121.49 (C-28), 121.81 (C-26,30), 122.55 (C-10), 124.05 (C-8), 124.25 (C-22), 126.49 (C-15), 127.15 (C-12), 127.38 (C-21,23), 127.49 (C-40), 127.68 (C-27,29), 128.12 (C-41), 128.68 (C-38), 129.44 (C-20,24), 129.74 (C-39), 131.29 (C-17), 131.40 (C-37), 132.58 (C-25), 135.18 (C-36), 136.21 (C-5), 137.37 (C-19), 141.75 (C-13), 142.46 (C-7), 146.09 (C-9), 160.95 (C-4), 163.22 (C-2), 164.63 (C-32,35). Anal. Calcd. for C₃₅H₂₁Cl₃N₅O₂: C, 54.11; H, 2.72; N, 9.02. Found: C, 54.18; H, 2.76; N, 8.95.
3-{4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)amino]-benzyl}quinazolin-4(3H)-one (10d)

Yield: 59%, mp: 245–248°C. IR (KBr), v, cm\(^{-1}\): 748 (C-Cl), 1318 (C-N), 1275, 1045 (C-O-C oxadiazole), 1613 (C=N quinazolinone), 1658 (C=N oxadiazole), 2925, 2852 (CH\(_2\)), 3451 (NH). \^H NMR (400 MHz, DMSO-\textit{d}_6, TMS): δ 3.52 (s, 2H, H-11), 6.40 (d, \(J = 7.88\) Hz, 1H, H-14), 6.89 (t, \(J = 7.36\) Hz, 1H, H-16), 7.40-7.09 (m, 2H, H-15,22), 7.21 (d, \(J = 7.5\) Hz, 1H, H-17), 7.42 (d, \(J = 8.08\) Hz, 2H, H-21,23), 7.45 (d, \(J = 8.36\) Hz, 2H, H-26,30), 7.49 (t, \(J = 7.6\) Hz, 1H, H-6), 7.56 (d, \(J = 8.36\) Hz, 2H, H-27,29), 7.61 (d, \(J = 8.12\) Hz, 1H, H-8), 7.65 (d, \(J = 8.28\) Hz, 2H, H-37,41), 7.68 (d, \(J = 8.28\) Hz, 2H, H-38,40), 7.75 (t, \(J = 7.8\) Hz, 1H, H-7), 8.09 (d, \(J = 7.68\) Hz, 1H, H-5), 9.10 (bs, 1H, H-18). \^C NMR (100 MHz, DMSO-\textit{d}_6, TMS): δ 32.61 (C-11), 116.25 (C-16), 120.43 (C-14), 121.52 (C-28), 121.78 (C-26,30), 122.57 (C-15), 124.32 (C-22), 125.51 (C-10), 125.72 (C-28), 125.76 (C-6), 127.68 (C-27,29), 128.74 (C-5), 129.38 (C-17), 131.63 (C-37,41), 132.59 (C-25), 133.19 (C-38,40), 133.64 (C-7), 135.42 (C-39), 137.34 (C-19), 141.65 (C-13), 147.13 (C-9), 160.77 (C-4), 163.38 (C-2), 164.61 (C-32,35). Anal. Calcd. for C\(_{35}\)H\(_{22}\)Cl\(_3\)N\(_5\)O\(_2\): C, 64.58; H, 3.41; N, 10.76. Found: C, 64.53; H, 3.44; N, 10.73.

6-Bromo-3-{4-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)amino]-benzyl}quinazolin-4(3H)-one (10e)

Yield: 68%, mp: 221–224°C. IR (KBr), v, cm\(^{-1}\): 565 (C-Br), 747 (C-Cl), 1317 (C-N), 1266, 1044 (C-O oxadiazoline), 1609 (C=N quinazolinone), 1650 (C=N oxadiazole), 1676 (C=O quinazolinone), 2923, 2852 (CH\(_2\)), 3446 (NH). \^H NMR (400 MHz, DMSO-\textit{d}_6, TMS): δ 3.53 (s, 2H, H-11), 6.41 (d, \(J = 7.96\) Hz, 1H, H-14), 6.90 (t, \(J = 7.4\) Hz, 1H, H-16), 7.04-7.10 (m, 2H, H-15,22), 7.20 (d, \(J = 7.58\) Hz, 1H, H-17), 7.42 (d, \(J = 8.12\) Hz, 2H, H-21,23), 7.46 (d, \(J = 8.4\) Hz, 2H, H-26,30), 7.56 (d, \(J = 8.4\) Hz, 2H, H-27,29), 7.60 (d, \(J = 8.28\) Hz, 1H, H-8), 7.64 (d, \(J = 8.28\) Hz, 2H, H-37,41), 8.07 (d, \(J = 8.28\) Hz, 1H, H-7), 8.13 (s, 1H, H-5), 9.11 (bs, 1H, H-18). \^C NMR (100 MHz, DMSO-\textit{d}_6, TMS): δ 32.67 (C-11), 116.25 (C-16), 120.56 (C-14), 121.53 (C-28), 121.79 (C-26,30), 123.16 (C-10), 123.32 (C-36), 124.27 (C-8), 124.56 (C-22), 124.56 (C-6), 127.62 (C-6), 127.74 (C-37,29), 129.38 (C-20,24), 131.22 (C-13), 131.82 (C-37,41), 132.28 (C-5), 132.62 (C-25), 133.28 (C-38,40), 133.64 (C-7), 135.42 (C-39), 137.34 (C-19), 141.65 (C-13), 147.13 (C-9), 160.77 (C-4), 163.38 (C-2), 164.61 (C-32,35). Anal. Calcd. for C\(_{35}\)H\(_{21}\)BrCl\(_3\)N\(_5\)O\(_2\): C, 57.60; H, 2.90; N, 9.60. Found: C, 57.53; H, 2.93; N, 9.55.

3-{4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]phenyl}-2-{2-[(2,6-dichlorophenyl)amino]-benzyl}-6-iodoquinazolin-4(3H)-one (10f)

Yield: 65%, mp: 257–261°C. IR (KBr), v, cm\(^{-1}\): 617 (C-I), 745 (C-Cl), 1314 (C-N), 1268, 1052 (C-O oxadiazoline), 1608 (C=N quinazolinone), 1652 (C=N oxadiazole), 1679 (C=O quinazolinone), 2925, 2851 (CH\(_2\)), 3443 (NH). \^H NMR (400 MHz, DMSO-\textit{d}_6, TMS): δ 3.51 (s, 2H, H-11), 6.39 (d, \(J = 8\) Hz, 1H, H-14), 6.88 (t, \(J = 7.48\) Hz, 1H, H-16), 7.03-7.10 (m, 2H, H-15,22), 7.20 (d, \(J = 7.58\) Hz, 1H, H-17), 7.24 (d, \(J = 8.24\) Hz, 1H, H-8), 7.43 (d, \(J = 8.16\) Hz, 2H, H-21,23), 7.47 (d, \(J = 8.32\) Hz, 2H, H-26,30), 7.58 (d, \(J = 8.32\) Hz, 2H, H-27,29), 7.63 (d, \(J = 8.2\) Hz, 2H, H-38,40), 7.68 (d, \(J = 8.2\) Hz, 2H, H-37,41), 7.95 (d, \(J = 8.24\) Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.12 (bs, 1H, H-18). \^C NMR (100 MHz, DMSO-\textit{d}_6, TMS): δ 33.01 (C-11), 93.20 (C-6), 116.21 (C-16), 120.43 (C-14), 121.48 (C-28), 121.76.
Synthesis and Antimicrobial Activity of 3-(1,3,4-Oxadiazol-2-yl)quinazolin-4(3H)-ones 185

Sci Pharm. 2010; 78: 171–193.

(C-26,30), 122.55 (C-10), 123.34 (C-36), 124.06 (C-8), 124.25 (C-22), 126.48 (C-15), 127.14 (C-12), 127.32 (C-21,23), 127.67 (C-27,29), 129.43 (C-20,24), 131.33 (C-17), 131.82 (C-37,41), 132.63 (C-25), 133.23 (C-38,40), 135.44 (C-39), 136.28 (C-5), 137.34 (C-19), 141.76 (C-13), 142.48 (C-7), 146.15 (C-9), 160.93 (C-4), 163.31 (C-2), 164.59 (C-32,35). Anal. Calcd. for C_{35}H_{21}Cl_{3}N_{5}O_{2}: C, 54.11; H, 2.72; N, 9.02. Found: C, 54.06; H, 2.75; N, 9.09.

**General procedure for quinazolin-4(3H)-ones (11a–c)**

A mixture of benzoxazinones 8a–c (5 mmol) and glycine (5 mmol) was refluxed in 20 ml butanol for 6-8 h. After completion of the reaction, it was concentrated and after cooling, water was added and solid thus obtained was filtered off and recrystallized from ethanol.

![Fig. 6. Numbering of Quinazolin-4(3H)-ones 11a–c](image)

**[2-{2-[(2,6-Dichlorophenyl)amino]benzyl}-4-oxoquinazolin-3(4H)-yl]acetic acid (11a)**

Yield: 53%, mp: 202–206°C. IR (KBr), v, cm\(^{-1}\): 741 (C-Cl), 1315 (C-N), 1608 (C=O quinazolinone), 1686 (C=O quinazolinone), 1715 (C=O), 2780 (OH), 2924, 2851 (CH\(_2\)), 3447 (NH). \(^1\)H NMR (400 MHz, DMSO-\(d_6\), TMS): δ 3.52 (s, 2H, H-11), 4.15 (s, 2H, H-25), 6.39 (d, \(J = 7.96\) Hz, 1H, H-14), 6.88 (t, \(J = 7.44\) Hz, 1H, H-16), 7.04-7.09 (m, 2H, H-15,22), 7.21 (d, \(J = 7.58\) Hz, 1H, H-17), 7.42 (d, \(J = 8.08\) Hz, 2H, H-21,23), 7.48 (t, \(J = 7.72\) Hz, 1H, H-6), 7.62 (d, \(J = 8.2\) Hz, 1H, H-8), 7.75 (t, \(J = 7.88\) Hz, 1H, H-7), 8.10 (d, \(J = 7.8\) Hz, 1H, H-5), 9.10 (bs, 1H, H-18), 12.34 (bs, 1H, H-26). \(^1\)C NMR (100 MHz, DMSO-\(d_6\), TMS): δ 32.62 (C-11), 42.93 (C-25), 116.31 (C-16), 120.44 (C-14), 120.91 (C-10), 122.52 (C-8), 124.29 (C-22), 126.51 (C-15), 127.18 (C-12), 127.37 (C-21,23), 127.82 (C-6), 128.71 (C-5), 129.32 (C-20,24), 131.14 (C-17), 135.74 (C-7), 137.28 (C-19), 141.71 (C-13), 147.13 (C-9), 160.72 (C-4), 164.63 (C-2), 173.52 (C-26). Anal. Calcd. for C\(_{23}\)H\(_{17}\)Cl\(_2\)N\(_3\)O\(_3\): C, 60.81; H, 3.77; N, 9.25. Found: C, 60.75; H, 3.70; N, 9.28.

**[6-Bromo-2-{2-[(2,6-dichlorophenyl)amino]benzyl}-4-oxoquinazolin-3(4H)-yl]acetic acid (11b)**

Yield: 56%, mp: 223–227°C. IR (KBr), v, cm\(^{-1}\): 567 (C-Br), 744 (C-Cl), 1317 (C-N), 1610 (C=N quinazolinone), 1684 (C=O quinazolinone), 1718 (C=O), 2785 (OH), 2925, 2849 (CH\(_2\)), 3445 (NH). \(^1\)H NMR (400 MHz, DMSO-\(d_6\), TMS): δ 3.53 (s, 2H, H-11), 4.14 (s, 2H, H-25), 6.40 (d, \(J = 8\) Hz, 1H, H-14), 6.88 (t, \(J = 7.4\) Hz, 1H, H-16), 7.03-7.08 (m, 2H, H-15,22), 7.22 (d, \(J = 7.5\) Hz, 1H, H-17), 7.41 (d, \(J = 8.12\) Hz, 2H, H-21,23), 7.63 (d, \(J = 8.36\) Hz, 1H, H-5).
Hz, 1H, H-8), 7.95 (d, J = 8.36 Hz, 1H, H-7), 8.03 (s, 1H, H-5), 9.09 (bs, 1H, H-18), 12.35 (bs, 1H, H-26). 13C NMR (100 MHz, DMSO-d6, TMS): δ 32.73 (C-11), 43.32 (C-25), 116.28 (C-16), 120.57 (C-14), 121.65 (C-6), 122.94 (C-10), 124.19 (C-22), 124.51 (C-8), 126.42 (C-15), 127.15 (C-12), 127.38 (C-21,23), 129.31 (C-20,24), 131.22 (C-17), 132.14 (C-5), 137.37 (C-19), 138.33 (C-7), 141.81 (C-13), 145.83 (C-9), 160.93 (C-4), 164.55 (C-2), 173.47 (C-26). Anal. Calcd. for C23H16BrCl2N3O3: C, 51.81; H, 3.02; N, 7.88. Found: C, 51.85; H, 3.05; N, 7.84.

[2-{2-[(2,6-Dichlorophenyl)amino]benzyl}-6-iodo-4-oxoquinazolin-3(4H)-yl]acetic acid (11c)
Yield: 60%, mp: 211–214°C. IR (KBr), v, cm⁻¹: 618 (C-I), 746 (C-Cl), 1318 (C-N), 1612 (C=N quinazolinone), 1682 (C=O quinazolinone), 1713 (C=O), 2778 (OH), 2922, 2846 (CH₂), 3443 (NH). 1H NMR (400 MHz, DMSO-d6, TMS): δ 3.53 (s, 2H, H-11), 4.16 (s, 2H, H-25), 6.41 (d, J = 7.92 Hz, 1H, H-14), 6.89 (t, J = 7.36 Hz, 1H, H-16), 7.26 (d, J = 8.32 Hz, 1H, H-8), 7.42 (d, J = 8.04 Hz, 2H, H-21,23), 7.94 (d, J = 8.32 Hz, 1H, H-7), 8.27 (s, 1H, H-5), 9.09 (bs, 1H, H-18), 12.35 (bs, 1H, H-26). 13C NMR (100 MHz, DMSO-d6, TMS): δ 33.12 (C-11), 43.26 (C-25), 93.32 (C-6), 116.26 (C-16), 120.51 (C-14), 122.52 (C-10), 123.92 (C-8), 124.13 (C-22), 126.58 (C-15), 126.98 (C-12), 127.26 (C-21,23), 129.32 (C-20,24), 131.24 (C-17), 136.14 (C-5), 137.28 (C-19), 141.67 (C-13), 142.45 (C-7), 145.74 (C-9), 161.16 (C-4), 164.62 (C-2), 173.44 (C-26). Anal. Calcd. for C23H16Cl2IN3O3: C, 47.61; H, 2.78; N, 7.24. Found: C, 47.57; H, 2.75; N, 7.25.

General procedure for 1,3,4-oxadiazolyl-quinazolin-4(3H)-ones (12a–f)
A mixture of 11a–c (2.5 mmol), benzohydrazides 3a,b (2.5 mmol) and 7 ml phosphorus trichloride in 10 ml dry benzene was refluxed under anhydrous condition for 10-12 h. After completion of reaction, benzene was distilled off under reduced pressure and the residue poured on to crushed ice and neutralized with sodium bicarbonate (5% w/v). The solid thus obtained was filtered, washed with cold water and recrystallized from ethanol.

Fig. 7. Numbering of 1,3,4-Oxadiazolyl-quinazolin-4(3H)-ones 12a–f

3-{[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]methyl}-2-{2-[(2,6-dichlorophenyl)amino]benzyl}quinazolin-4(3H)-one (12a)
Yield: 72%, mp: 181–184°C. IR (KBr), v, cm⁻¹: 744 (C-Cl), 1313 (C-N), 1259, 1035 (C-O-C oxadiazole), 1611 (C=N quinazolinone), 1653 (C=N oxadiazole), 1678 (C=O)
quinazolinone), 2923, 2855 (CH₂), 3448 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.51 (s, 2H, H-11), 4.49 (s, 2H, H-25), 6.40 (d, J = 7.96 Hz, 1H, H-14), 6.89 (t, J = 7.44 Hz, 1H, H-16), 7.05-7.10 (m, 2H, H-15,22), 7.22 (d, J = 7.58 Hz, 1H, H-17), 7.42 (d, J = 8.12 Hz, 2H, H-21,23), 7.47 (t, J = 7.56 Hz, 1H, H-34), 7.51 (t, J = 7.64 Hz, 1H, H-6), 7.56 (t, J = 7.4 Hz, 1H, H-35), 7.61 (d, J = 8.12 Hz, 1H, H-8), 7.67 (d, J = 7.84 Hz, 1H, H-33), 7.71 (d, J = 7.48 Hz, 1H, H-36), 7.75 (t, J = 7.8 Hz, 1H, H-7), 8.09 (d, J = 7.72 Hz, 1H, H-5), 9.10 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 33.02 (C-11), 42.42 (C-25), 116.32 (C-16), 120.45 (C-14), 120.93 (C-10), 122.57 (C-8), 124.31 (C-22), 126.54 (C-15), 127.22 (C-12), 127.39 (C-21,23), 127.61 (C-35), 127.83 (C-6), 128.24 (C-36), 128.73 (C-5), 128.82 (C-33), 129.37 (C-20,24), 129.75 (C-34), 131.18 (C-17), 131.79 (C-32), 135.47 (C-31), 135.81 (C-7), 137.34 (C-19), 141.75 (C-13), 147.18 (C-9), 156.28 (C-27), 160.74 (C-4), 163.46 (C-2), 164.65 (C-30). Anal. Calcd. for C₃₀H₂₀Cl₃N₅O₂: C, 61.19; H, 3.42; N, 11.89. Found: C, 61.12; H, 3.47; N, 11.85.

6-Bromo-3-[[5-([2-chlorophenyl]-1,3,4-oxadiazol-2-yl)methyl]-2-[[2-(6-dichlorophenyl)-amino]benzyl]quinazolin-4(3H)-one (12b)

Yield: 68%, mp: 175–178°C. IR (KBr), ν, cm⁻¹: 568 (C-Br), 742 (C-Cl), 1311 (C-N), 1263, 1045 (C=O oxadiazole), 1612 (C=N quinazolinone), 1653 (C=N oxadiazole), 1675 (C=O
quinazolinone), 2922, 2850 (CH₂), 3443 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.53 (s, 2H, H-11), 4.48 (s, 2H, H-25), 6.40 (d, J = 8 Hz, 1H, H-14), 6.88 (t, J = 7.48 Hz, 1H, H-16), 7.03-7.08 (m, 2H, H-15,22), 7.22 (d, J = 7.58 Hz, 1H, H-17), 7.41 (d, J = 8.08 Hz, 2H, H-21,23), 7.49 (t, J = 7.52 Hz, 1H, H-34), 7.56 (t, J = 7.36 Hz, 1H, H-35), 7.62 (d, J = 8.28 Hz, 1H, H-8), 7.67 (d, J = 7.8 Hz, 1H, H-33), 7.72 (d, J = 7.48 Hz, 1H, H-36), 8.06 (d, J = 8.28 Hz, 1H, H-7), 8.11 (s, 1H, H-5), 9.10 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 33.14 (C-11), 42.47 (C-25), 116.32 (C-16), 120.63 (C-14), 121.68 (C-6), 122.96 (C-10), 124.22 (C-22), 124.54 (C-8), 126.46 (C-15), 127.17 (C-12), 127.42 (C-21,23), 127.67 (C-35), 128.26 (C-36), 128.72 (C-33), 129.35 (C-20,24), 129.69 (C-34), 131.24 (C-17), 131.84 (C-32), 132.16 (C-5), 135.52 (C-31), 137.43 (C-19), 138.37 (C-7), 141.84 (C-13), 145.85 (C-9), 156.25 (C-27), 160.97 (C-4), 163.41 (C-2), 164.56 (C-30). Anal. Calcd. for C₃₀H₁₉BrCl₃N₅O₂: C, 53.96; H, 2.87; N, 10.49. Found: C, 53.88; H, 2.85; N, 10.53.

3-[[5-([2-Chlorophenyl]-1,3,4-oxadiazol-2-yl)methyl]-2-[[2-(6-dichlorophenyl)amino]benzyl]6-idoquinazolin-4(3H)-one (12c)

Yield: 62%, mp: 196–198°C. IR (KBr), ν, cm⁻¹: 620 (C-I), 745 (C-Cl), 1316 (C-N), 1265, 1036 (C=O oxadiazole), 1609 (C=N quinazolinone), 1650 (C=N oxadiazole), 1678 (C=O quinazolinone), 2924, 2850 (CH₂), 3445 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.53 (s, 2H, H-11), 4.48 (s, 2H, H-25), 6.41 (d, J = 8 Hz, 1H, H-14), 6.89 (t, J = 7.48 Hz, 1H, H-16), 7.04-7.09 (m, 2H, H-15,22), 7.22 (d, J = 7.62 Hz, 1H, H-17), 7.26 (d, J = 8.36 Hz, 1H, H-8), 7.42 (d, J = 8.12 Hz, 2H, H-21,23), 7.50 (t, J = 7.52 Hz, 1H, H-34), 7.56 (t, J = 7.36 Hz, 1H, H-35), 7.65 (d, J = 8.36 Hz, 1H, H-7), 8.27 (s, 1H, H-5), 9.09 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 33.51 (C-11), 42.47 (C-25), 93.33 (C-6), 116.27 (C-16), 120.53 (C-14), 122.55 (C-10), 123.91 (C-8), 124.16 (C-22), 126.62 (C-15), 127.11 (C-12), 127.28 (C-21,23), 127.64 (C-35), 128.26 (C-36), 128.73 (C-33), 129.37 (C-20,24), 129.75 (C-34), 131.28 (C-17), 131.84 (C-32), 136.15 (C-5), 135.52 (C-31), 137.31 (C-19), 141.70 (C-13), 142.48 (C-7), 145.77 (C-9), 156.23 (C-27), 161.18 (C-4), 163.44 (C-2), 164.67 (C-30). Anal. Calcd. for C₃₀H₁₉BrCl₃N₅O₂: C, 50.41; H, 2.68; N, 9.80. Found: C, 50.45; H, 2.71; N, 9.73.
3-[(5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl)methyl]-2-[(2,6-dichlorophenyl)amino]-benzyl]quinoxazolin-4(3H)-one (12d)

Yield: 71%, mp: 227–30°C. IR (KBr), ν, cm⁻¹: 748 (C-Cl), 1316 (C-N), 1254, 1038 (C-O-C oxadiazole), 1608 (C=N quinoxazolinone), 1655 (C=N oxadiazole), 1683 (C=O quinoxazolinone), 2922, 2851 (CH₂), 3443 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.52 (s, 2H, H-11), 4.47 (s, 2H, H-25), 6.39 (d, J = 8.04 Hz, 1H, H-14), 6.88 (t, J = 7.52 Hz, 1H, H-16), 7.04-7.09 (m, 2H, H-15,22), 7.21 (d, J = 7.62 Hz, 1H, H-17), 7.42 (d, J = 8.16 Hz, 2H, H-21,23), 7.50 (t, J = 7.68 Hz, 1H, H-6), 7.62 (d, J = 18.16 Hz, 1H, H-8), 7.65 (d, J = 8.2 Hz, 2H, H-33,35), 7.70 (d, J = 8.2 Hz, 2H, H-32,36), 7.74 (t, J = 7.84 Hz, 1H, H-7), 8.08 (d, J = 7.76 Hz, 1H, H-5), 9.12 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 33.05 (C-11), 42.23 (C-25), 116.35 (C-16), 120.48 (C-14), 122.55 (C-8), 123.34 (C-31), 126.53 (C-15), 127.26 (C-12), 127.34 (C-21,23), 127.77 (C-6), 128.74 (C-5), 129.35 (C-20,24), 131.21 (C-17), 131.83 (C-32,36), 133.26 (C-33,35), 135.38 (C-34), 135.78 (C-7), 137.36 (C-19), 141.76 (C-13), 147.18 (C-9), 156.27 (C-27), 160.78 (C-4), 163.38 (C-2), 164.67 (C-30). Anal. Calcd. for C₃₀H₂₀Cl₃N₅O₂: C, 61.19; H, 3.42; N, 11.89. Found: C, 61.22; H, 3.38; N, 11.84.

6-Bromo-3-[(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)methyl]-2-[(2,6-dichlorophenyl)amino]-benzyl]quinoxazolin-4(3H)-one (12e)

Yield: 67%, mp: 266–69°C. IR (KBr), ν, cm⁻¹: 571 (C-Br), 750 (C-Cl), 1313 (C-N), 1260, 1049 (C-O-C oxadiazole), 1607 (C=N quinoxazolinone), 1678 (C=O quinoxazolinone), 2925, 2853 (CH₂), 3448 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.53 (s, 2H, H-11), 4.49 (s, 2H, H-25), 6.40 (d, J = 7.88 Hz, 1H, H-14), 6.89 (t, J = 7.32 Hz, 1H, H-16), 7.02-7.08 (m, 2H, H-15,22), 7.20 (d, J = 7.46 Hz, 1H, H-17), 7.42 (d, J = 8.04 Hz, 2H, H-21,23), 7.61 (d, J = 8.2 Hz, 1H, H-8), 7.65 (d, J = 8.2 Hz, 2H, H-33,35), 7.72 (d, J = 8.2 Hz, 2H, H-32,36), 8.05 (d, J = 8.32 Hz, 1H, H-7), 8.12 (s, 1H, H-5), 9.08 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 33.15 (C-11), 42.51 (C-25), 116.25 (C-16), 120.54 (C-14), 121.63 (C-6), 122.87 (C-10), 123.30 (C-31), 124.34 (C-22), 124.46 (C-8), 126.38 (C-15), 127.17 (C-12), 127.42 (C-21,23), 129.28 (C-20,24), 131.25 (C-17), 131.78 (C-32,36), 132.12 (C-5), 133.23 (C-33,35), 135.46 (C-34), 137.42 (C-19), 138.32 (C-7), 141.83 (C-13), 145.85 (C-9), 156.31 (C-27), 160.94 (C-4), 163.37 (C-2), 164.57 (C-30). Anal. Calcd. for C₃₀H₁₉BrCl₃N₅O₂: C, 53.96; H, 2.87; N, 10.49. Found: C, 53.91; H, 2.82; N, 10.48.

3-[(5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl)methyl]-6-iodoquinoxazolin-4(3H)-one (12f)

Yield: 75%, mp: 243–46°C. IR (KBr), ν, cm⁻¹: 618 (C-I), 749 (C-Cl), 1315 (C-N), 1260, 1049 (C-O-C oxadiazole), 1611 (C=N quinoxazolinone), 1658 (C=N oxadiazole), 1683 (C=O quinoxazolinone), 2921, 2849 (CH₂), 3445 (NH). ¹H NMR (400 MHz, DMSO-d₆, TMS): δ 3.51 (s, 2H, H-11), 4.48 (s, 2H, H-25), 6.42 (d, J = 7.96 Hz, 1H, H-14), 6.90 (t, J = 7.4 Hz, 1H, H-16), 7.03-7.08 (m, 2H, H-15,22), 7.21 (dd, J = 7.5 Hz, 1.28 Hz, 1H, H-17), 7.24 (d, J = 8.4 Hz, 1H, H-8), 7.41 (d, J = 8.12 Hz, 2H, H-21,23), 7.62 (d, J = 8.2 Hz, 2H, H-33,35), 7.68 (d, J = 8.2 Hz, 2H, H-32,36), 7.93 (d, J = 8.4 Hz, 1H, H-7), 8.28 (s, 1H, H-5), 9.12 (bs, 1H, H-18). ¹³C NMR (100 MHz, DMSO-d₆, TMS): δ 33.47 (C-11), 42.51 (C-25), 116.25 (C-16), 120.54 (C-14), 121.63 (C-6), 122.87 (C-10), 123.30 (C-31), 124.15 (C-22), 124.46 (C-8), 126.38 (C-15), 127.17 (C-12), 127.42 (C-21,23), 129.28 (C-20,24), 131.25 (C-17), 131.78 (C-32,36), 132.12 (C-5), 133.23 (C-33,35), 135.46 (C-34), 137.42 (C-19), 138.32 (C-7), 141.83 (C-13), 145.85 (C-9), 156.31 (C-27), 160.94 (C-4), 163.37 (C-2), 164.57 (C-30). Anal. Calcd. for C₃₀H₁₉BrCl₃N₅O₂: C, 53.96; H, 2.87; N, 10.49. Found: C, 53.91; H, 2.82; N, 10.48.

Sci Pharm. 2010; 78: 171–193.
(C-13), 142.48 (C-7), 145.76 (C-9), 156.31 (C-27), 161.14 (C-4), 163.49 (C-2), 164.63 (C-30). Anal. Calcd. for C$_{30}$H$_{19}$Cl$_3$IN$_5$O$_2$: C, 50.41; H, 2.68; N, 9.80. Found: C, 50.35; H, 2.76; N, 9.77.

**Antimicrobial activity**

The MICs of synthesized compounds were carried out by broth microdilution method as described by Rattan [35]. Antibacterial activity was screened against two gram positive bacteria (S. aureus MTCC 96, S. pyogenes MTCC 442) and two gram negative bacteria (E. coli MTCC 443, P. aeruginosa MTCC 1688). Ampicillin was used as a standard antibacterial agent. Antifungal activity was screened against three fungal species C. albicans MTCC 227, A. niger MTCC 282 and A. clavatus MTCC 1323. Griseofulvin was used as a standard antifungal agent.

All MTCC cultures were collected from Institute of Microbial Technology, Chandigarh and tested against above mentioned known drugs. Mueller hinton broth was used as nutrient medium to grow and dilute the drug suspension for the test. Inoculum size for test strain was adjust to $10^8$ CFU (Colony Forming Unit) per milliliter by comparing the turbidity. DMSO was used as diluents to get desired concentration of drugs to test upon standard bacterial strains. Serial dilutions were prepared in primary and secondary screening. The control tube containing no antibiotic was immediately sub cultured (before inoculation) by spreading a loopful evenly over a quarter of plate of medium suitable for the growth of the test organism and put for incubation at 37 °C overnight. The tubes were then incubated overnight. The MIC of the control organism was read to check the accuracy of the drug concentrations. The lowest concentration inhibiting growth of the organism was recorded as the MIC. All the tubes not showing visible growth (in the same manner as control tube described above) was sub cultured and incubated overnight at 37 °C. The amount of growth from the control tube before incubation (which represents the original inoculum) was compared. Subcultures might show: similar number of colonies indicating bacteriostatic; a reduced number of colonies indicating a partial or slow bactericidal activity and no growth if the whole inoculum has been killed. The test must include a second set of the same dilutions inoculated with an organism of known sensitivity. Each synthesized drug was diluted obtaining 2000 µg/ml concentration, as a stock solution. In primary screening 500 µg/ml, 250 µg/ml and 125 µg/ml concentrations of the synthesized drugs were taken. The active synthesized drugs found in this primary screening were further tested in a second set of dilution against all microorganisms. The drugs found active in primary screening were similarly diluted to obtain 100 µg/ml, 50 µg/ml, 25 µg/ml, 12.5 µg/ml, 6.250 µg/ml, 3.125 µg/ml and 1.5625 µg/ml concentrations. The highest dilution showing at least 99 % inhibition is taken as MIC.

**Conclusions**

Aminosubstituted 1,3,4-oxadiazoles 4a,b and 5a,b exhibited very good antimicrobial activity. But when they were condensed with benzoazinone formed oxadiazolyl-quinazolinone, showed increasing activity. Antimicrobial results were found uneven but most of the bromo and iodo derivatives of quinazolinone possessed very good antimicrobial activity. Furthermore CH$_2$ link between 3rd position of quinazolinone and 2nd position of oxadiazole were found most active than other two series. So, it seems from the
antimicrobial results that halogen atom and CH₂ link played vital role in increasing antimicrobial activity.

Acknowledgement
The authors are thankful to Veer Narmad South Gujarat University for providing necessary facilities, CDRI Lucknow and SAIF Chandigarh for spectral analysis of the compounds. Thank to Dhanji Rajani for antimicrobial activity screening.

Authors’ Statement

Competing Interests
The authors declare no conflict of interest.

References

[1] Zheng X, Li Z, Wang Y, Chen W, Huang Q, Liu C, Song G. Syntheses and insecticidal activities of novel 2,5-disubstituted 1,3,4-oxadiazoles. J Fluorine Chem. 2003; 123: 163-169. doi:10.1016/S0022-1139(03)00168-4

[2] Chavan VP, Sonawane SA, Shingare MS, Karale BK. Synthesis, characterization, and biological activities of some 3,5,6-trichloropyridine derivatives. Chem Heterocyclic Compounds. 2006; 42: 625-630. doi:10.1007/s10593-006-0137-8

[3] Hollaa BS, Gonsalves R, Shenoy S. Synthesis and antibacterial studies of a new series of 1,2-bis(1,3,4-oxadiazol-2-yl)ethanes and 1,2-bis(4-amino-1,2,4-triazol-3-yl)ethanes. Eur J Med Chem. 2000; 35: 267-271. doi:10.1016/S0223-5234(00)00154-9

[4] Liu F, Luo X, Song B, Bhadury PS, Yang S, Jin L, Xue W, Hu D. Synthesis and antifungal activity of novel sulfoxide derivatives containing trimethoxyphenyl substituted 1,3,4-thiadiazole and 1,3,4-oxadiazole moiety. Bioorg Med Chem. 2008; 16: 3632-3640. doi:10.1016/j.bmc.2008.02.006

[5] Narayana B, Raj KKV, Ashalatha BV, Kumari NS. Synthesis of some new 2-(6-methoxy-2-naphthyl)-5-aryl-1,3,4-oxadiazoles as possible non-steroidal anti-inflammatory and analgesic agents. Arch Pharm. 2005; 338: 373-377. doi:10.1002/ardp.200500974

[6] Koksal M, Bilge SS, Bozkurt A, Sahin ZS, Isik S, Erol DD. Synthesis, characterization and anti-inflammatory activity of new 5-(3,4-dichlorophenyl)-2-(arylmethylothio)-1,3,4-oxadiazoles. Arzneimittel-Forschung. 2008; 58: 510-514.

[7] Zareef M, Iqbal R, Dominguez NG, Rodrigues J, Zaidi JH, Arfan M, Supuran CT. Synthesis and antimalarial activity of novel chiral and achiral benzenesulfonamides bearing 1,3,4-oxadiazole moieties. J Enz Inhib Med Chem. 2007; 22: 301-308. doi:10.1080/14756360601114569

[8] Farghaly AR, El-Kashef H. Synthesis of some new azoles with antiviral potential¹. Arkivoc. 2006; 11: 76-90.
[9] El-Essawy FA, Khattab AF, Abdel-Rahman AAH. Synthesis of 1,2,4-triazol-3-ylmethyl-, 1,3,4-oxa-, and thiadiazol-2-ylmethyl-1H-[1,2,3]-triazolo[4,5-d]pyrimidinediones. Monatsh Chem. 2007; 138: 777-785. doi:10.1007/s00706-007-0649-7

[10] Amr AEE, Mohamed SF, Abdel-Hafez NA, Abdalla MM. Antianxiety activity of pyridine derivatives synthesized from 2-chloro-6-hydrazino-isonicotinic acid hydrazide. Monatsh Chem. 2008; 139: 1491-1498. doi:10.1007/s00706-008-0949-6

[11] Kumar A, D’Souza SS, Gaonkar SL, Rai KML, Salimath BP. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by a new series of substituted-1,3,4-oxadiazole derivatives. Invest New Drugs. 2008; 26: 425-435. doi:10.1007/s10637-008-9116-5

[12] Zareef M, Iqbal R, Al-Masoudi NA, Zaidi JH, Arfan M, Shahzad SA. Synthesis, anti-HIV, and antifungal activity of new benzensulfonamides bearing the 2,5-disubstituted-1,3,4-oxadiazole moiety. Phosphorus Sulfur and Silicon. 2007; 182: 281-298. doi:10.1080/10426500600919074

[13] Macaev F, Rusu G, Pogrebnoi S, Gudima A, Stingaci E, Vlad L, Shvets N, Kandemirli F, Dimogloa A, Reynolds R. Synthesis of novel 5-aryl-2-thio-1,3,4-oxadiazoles and the study of their structure-anti-mycobacterial activities. Bioorg Med Chem. 2005; 13: 4842-4850. doi:10.1016/j.bmc.2005.05.011

[14] Zarghi A, Tabatabai SA, Faizi M, Ahadian A, Navabi P, Zanganeh V, Shafiee A. Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazoles. Bioorg Med Chem Lett. 2005; 15: 1863-1865. doi:10.1016/j.bmcl.2005.02.014

[15] Alafeefy AM. Synthesis and antimicrobial activity of some new quinazolin-4(3H)-one derivatives. Pharm Biol. 2008; 46: 751-756. doi:10.1080/13880200802315907

[16] Sen Gupta AK, Misra HK. Synthesis and evaluation of substituted quinazolone derivatives for antibacterial, antifungal, and antiacetylcholinesterase activities. J Pharm Sci. 1980; 69: 1313-1317. doi:10.1002/jps.260069120

[17] Alagarsamy V, Murugesan S, Sheorey RV. Synthesis and pharmacological investigation of novel 3-(benzy)-2-substituted amino-3H-quinazolin-4-ones as analgesic and anti-inflammatory agents. Med Chem Res. 2008; 17: 564-577. doi:10.1007/s00044-008-9098-z

[18] Jessy EM, Sambanthan AT, Alex J, Sridevi CH, Srinivasan KK. Synthesis and biological evaluation of some novel quinazolones. Indian J Pharm Sci. 2007; 69: 476-478.

[19] Shukla JS, Agarwal K, Rastogi R. Synthesis of some new 2-substituted 3-[4-(N-arylsulphonylbiguanido)phenyl]quinazolin-4-one hydrochlorides as potential anthelmintic agents. Arch Pharm. 1983; 316: 525-529. doi:10.1002/ardp.19833160610
[20] Khalil AA, Abdel Hamide SG, Al-Obaid AM, El-Subbagh HI. Substituted quinazolines, part 2. synthesis and in vitro anticancer evaluation of new 2-substituted mercapto-3H-quinazoline analogs. Arch Pharm. 2003; 336: 95-103. doi:0365-6233/02/0095

[21] Laddha SS, Bhatnagar SP. Rapid microwave-assisted solution phase synthesis of 6,8-disubstituted 2-phenyl-3-(substitutedbenzothiazol-2-yl)-4-[3H]-quinazolinones as novel anticonvulsants. Phosphorus Sulfur and Silicon. 2008; 183: 2262-2273. doi:10.1080/10426500801957766

[22] Alagarsamy V, Prabakaran L, Murugan RD, Gurumurth G, Bindu P, Arunkumar M, Bothiraja C. Synthesis and antihistaminic activity of some novel 2-mercapto-3-(substitutedmethylamino)quinazolin-4(3H)-ones. Acta Pharm Turcica. 2000; 42: 33-38.

[23] Alagarsamy V, Murugesan S, Dhanabal K, Murugan M, Clercq E. Anti-HIV, antibacterial and antifungal activities of some novel 2-methyl-3-(substituted methylamino)-(3H)-quinazolin-4-ones. Indian J Pharm Sci. 2007; 69: 304-307.

[24] Raffa D, Daidone G, Maggio B, Schilliaci D, Plescia F. Synthesis and antiproliferative activity of novel 3-(indazol-3-yl)-quinazolin-4(3H)-one and 3-(indazol-3-yl)-benzotriazin-4(3H)-one derivatives. Arch Pharm. 1999; 332: 317-320. doi:10.1002/(SICI)1521-4184(19999)332:9<317::AID-ARDP317>3.0.CO;2-R

[25] Mosaad SM, Mohammed KI, Ahmed MA, Abdel-Hamide SG. Synthesis of certain new 6-idoquinozines as potential antitubercular agents. J Applied Sci. 2004; 4: 302-307.

[26] Selvam P, Babu K, Padamraj R, Persoons L, Clercq E. Synthesis, antiviral and cytotoxic activities of some novel 2-phenyl-3-disubstituted quinazolin-4(3H)-ones. African J Pharm Pharmacol. 2008; 2: 110-115.

[27] Joshi KC, Singh VK, Mehta DS, Sharma RC, Gupta L. Fluorinated quinazolones iii: synthesis and CNS depressant activity of fluorinated quinazolone derivatives. J Pharm Sci. 1975; 64: 1428-1430. doi:10.1002/jps.2600640843

[28] Raffa D, Edler MC, Daidone G, Maggio B, Merickech M, Plescia S, Schilliaci D, Bai R, Hamel E. Synthesis, cytotoxicity, and inhibitory effects on tubulin polymerization of a new 3-heterocyclo substituted 2-styrylquinazolinones. Eur J Med Chem. 2004; 39: 299-304. doi:10.1016/j.ejmech.2003.12.009

[29] Maarouf AR, El-Bendary ER, Goda FE. Synthesis and evaluation of some novel quinazolinone derivatives as diuretic agents. Arch Pharm. 2004; 337: 527-532. doi:10.1002/ardp.200400869

[30] Kurogi Y, Inoue Y, Tsutsumi K, Nakamura S, Nagao K, Yoshitsugu H, Tsuda Y. Synthesis and hypolipidemic activities of novel 2-[4-[(diethoxyphosphoryl)methyl]phenyl]quinazolines and 4(3H)-quinazolinones. J Med Chem. 1996; 39: 1433-1437. doi:10.1021/jm9506938

[31] Furniss BS, Hannafoad AJ, Smith PWG, Tatchell AR. In: Vogel’s Textbook of Practical Organic Chemistry. 5th ed. New York: Wiley, 1989, 692.
[32] Katritzky AR, Vvedensky V, Cai X, Rogovoy B, Steel PJ. Syntheses of 5-(2-arylamino)-1,2,4-triazoles and 2-amino-5-aryl-1,3,4-oxadiazoles. Arkivoc. 2002; 6: 82-90.

[33] Patel NB, Chaudhari RC. Quinazolin-4(3H)-ones of 2-[(2',6'-dichlorophenyl)amino]phenyl acetic acid with substituted aryl acetamide and their microbial studies. J Ind Chem Soc. 2006; 83: 838–841.

[34] Patel NB, Lilakar JD. Synthesis of new substituted 4(3H)-quinazolinones and their antibacterial activity. Ind J Heterocycl Chem. 2001; 11: 85–86.

[35] Rattan A. In: Antimicrobials in laboratory medicine. New Delhi: Churchill BI, Livingstone, 2000, 85.